Endothelial Alterations in Pulmonary Hypertension

Clavé, M; Lopes, Antônio Augusto

doi:10.1016/b978-0-12-812348-5.00029-5

Cited by 1 publication

(4 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating (plasma) levels of P‐selectin, tissue‐type plasminogen activator (t‐PA), thrombomodulin, and von Willebrand factor antigen (VWF:Ag) were measured to assess endothelial dysfunction . Plasma β‐thromboglobulin was used as an index of endogenous platelet activation.…”

Section: Methodsmentioning

confidence: 99%

“…Plasma β‐thromboglobulin was used as an index of endogenous platelet activation. Soluble (plasma) CD40 ligand (sCD40L) was measured as a marker of interaction between platelets and endothelial cells . Table provides information about the cellular origin of these proteins, their targets, and principal biological and pathobiological actions.…”

Section: Methodsmentioning

confidence: 99%

“…Circulating (plasma) levels of P-selectin, tissue-type plasminogen activator (t-PA), thrombomodulin, and von Willebrand factor antigen (VWF:Ag) were measured to assess endothelial dysfunction. 25 Plasma β-thromboglobulin was used as an index of endogenous platelet activation. Soluble (plasma) CD40 ligand (sCD40L) was measured as a marker of interaction between platelets and endothelial cells.…”

Section: Microvascular Dysfunction Markersmentioning

confidence: 99%

“…Soluble (plasma) CD40 ligand (sCD40L) was measured as a marker of interaction between platelets and endothelial cells. 25 Table 1 provides information about the cellular origin of these proteins, their targets, and principal biological and pathobiological actions. Plasma samples were processed in duplicate using commercially available en-…”

Section: Microvascular Dysfunction Markersmentioning

confidence: 99%

See 3 more Smart Citations

Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease

Clavé

Maeda

Thomaz

et al. 2018

Congenital Heart Disease

View full text Add to dashboard Cite

Background: Ideally, vasodilator therapies for pulmonary arterial hypertension (PAH) should have a favorable impact on markers of vascular dysfunction, in addition to their known effects on hemodynamics, cardiac function, and patient's physical capacity. Methods:We analyzed circulating (plasma) markers of endothelial and platelet activation/dysfunction (enzyme-linked immunoassays) in the specific setting of advanced PAH associated with congenital heart disease, during the course of sildenafil and tadalafil therapies. Thirty-one patients were enrolled (age 10-54 years), most of them with chronic hypoxemia and elevated hematocrit. Drugs were administered orally for 6 months (sildenafil [n = 16], 20 mg t.i.d.; tadalafil [n = 15], single daily dose of 40 mg). Measurements were performed at baseline, and 90 and 180 days.Results: Compared to controls, patients had elevated baseline β-thromboglobulin (β-TG, P = .002), P-selectin (P = .027), tissue-type plasminogen activator (t-PA, P = .009), and von Willebrand factor antigen (VWF:Ag, P = .010). Thrombomodulin was importantly reduced (TM, P < .001), while soluble CD40 Ligand was not changed (P = .320). Tadalafil administration was associated with improvement of β-TG (P = .004), t-PA (P = .003) and TM (P = .046) levels, while P-selectin was improved by sildenafil treatment only (P = .034). VWF:Ag improved transiently in the sildenafil group (P = .019). Both therapies were associated with improvement of the physical capacity (functional class and distance walked during the 6-minute test, P < .05), hematocrit and hemoglobin level (P < .05), and health-related quality of life (physical and mental components, P < .05). Conclusion:In PAH associated with congenital heart disease, phosphodiesterase 5 inhibitors seem to have beneficial actions at microcirculatory level, beyond the proposed effects as vasodilators. K E Y W O R D Sbiomarkers, congenital heart disease, endothelial dysfunction, phosphodiesterase 5 inhibitors, platelets, pulmonary hypertension | 247 CLAVÉ et al.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Microvascular Dysfunction Markersmentioning

confidence: 99%

Section: Microvascular Dysfunction Markersmentioning

confidence: 99%

See 2 more Smart Citations